237 related articles for article (PubMed ID: 32298237)
1. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
3. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Barrera LN; Rushworth SA; Bowles KM; MacEwan DJ
Cell Cycle; 2012 Jun; 11(12):2248-52. PubMed ID: 22617388
[TBL] [Abstract][Full Text] [Related]
5. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
11. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
Yuan C; Yuan M; Li W; Cheng H; Luo J; Zhang Q; Shi M; Niu M; Yang J; Sun Z; Yan Z; Xu K; Li Z; Yao Y
Exp Cell Res; 2023 Aug; 429(1):113634. PubMed ID: 37207970
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
15. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.
Yao Y; Sun Y; Shi M; Xia D; Zhao K; Zeng L; Yao R; Zhang Y; Li Z; Niu M; Xu K
Oncotarget; 2016 Nov; 7(45):73497-73508. PubMed ID: 27634873
[TBL] [Abstract][Full Text] [Related]
16. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
[TBL] [Abstract][Full Text] [Related]
17. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Shi L; Wang S; Zangari M; Xu H; Cao TM; Xu C; Wu Y; Xiao F; Liu Y; Yang Y; Salama M; Li G; Tricot G; Zhan F
Oncotarget; 2010 May; 1(1):22-33. PubMed ID: 20930946
[TBL] [Abstract][Full Text] [Related]
19. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
20. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]